HighVista Strategies LLC Reduces Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN)

HighVista Strategies LLC trimmed its holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 5.6% in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 119,789 shares of the company’s stock after selling 7,065 shares during the quarter. Enliven Therapeutics comprises approximately 1.0% of HighVista Strategies LLC’s portfolio, making the stock its 26th biggest position. HighVista Strategies LLC owned about 0.25% of Enliven Therapeutics worth $2,799,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. China Universal Asset Management Co. Ltd. raised its stake in Enliven Therapeutics by 67.0% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 7,952 shares of the company’s stock valued at $140,000 after buying an additional 3,189 shares during the last quarter. EntryPoint Capital LLC purchased a new stake in Enliven Therapeutics during the first quarter valued at $167,000. Baker BROS. Advisors LP bought a new position in Enliven Therapeutics in the first quarter valued at about $2,020,000. Blackstone Inc. bought a new position in Enliven Therapeutics in the first quarter valued at about $443,000. Finally, Janus Henderson Group PLC boosted its position in Enliven Therapeutics by 74.8% in the first quarter. Janus Henderson Group PLC now owns 713,911 shares of the company’s stock worth $12,604,000 after purchasing an additional 305,397 shares during the last quarter. Institutional investors own 95.08% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the company. Robert W. Baird started coverage on Enliven Therapeutics in a research report on Tuesday, June 11th. They set an “outperform” rating and a $32.00 target price on the stock. Baird R W raised shares of Enliven Therapeutics to a “strong-buy” rating in a report on Tuesday, June 11th. Finally, HC Wainwright began coverage on Enliven Therapeutics in a report on Monday, September 9th. They set a “buy” rating and a $37.00 price target on the stock.

Enliven Therapeutics Price Performance

Enliven Therapeutics stock opened at $23.19 on Monday. Enliven Therapeutics, Inc. has a 1 year low of $9.80 and a 1 year high of $27.67. The firm’s 50 day moving average price is $23.05 and its 200-day moving average price is $21.25. The stock has a market cap of $1.09 billion, a P/E ratio of -12.02 and a beta of 1.09.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.17. As a group, equities analysts expect that Enliven Therapeutics, Inc. will post -1.98 EPS for the current year.

Insider Buying and Selling at Enliven Therapeutics

In other Enliven Therapeutics news, insider Joseph P. Lyssikatos sold 12,000 shares of Enliven Therapeutics stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $22.49, for a total value of $269,880.00. Following the completion of the transaction, the insider now directly owns 1,077,936 shares of the company’s stock, valued at approximately $24,242,780.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Enliven Therapeutics news, insider Joseph P. Lyssikatos sold 12,000 shares of the business’s stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $22.49, for a total transaction of $269,880.00. Following the transaction, the insider now owns 1,077,936 shares in the company, valued at $24,242,780.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Samuel Kintz sold 2,270 shares of Enliven Therapeutics stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $27.56, for a total transaction of $62,561.20. Following the transaction, the chief executive officer now directly owns 1,061,255 shares of the company’s stock, valued at $29,248,187.80. The disclosure for this sale can be found here. Insiders sold 135,805 shares of company stock worth $3,328,112 in the last quarter. 29.20% of the stock is owned by corporate insiders.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.